Literature DB >> 17880864

Reducing variation in the pharmacologic treatment of schizophrenia: defining acceptable standards of treatment.

Robert J Constantine1.   

Abstract

Clinicians are exhorted to improve the quality of care for patients with schizophrenia by applying evidence-based medication treatment guidelines. Unfortunately, although there are many guidelines, they are all more or less out of date, and their recommendations often are inconsistent, leaving clinicians uncertain about the definition of acceptable standards of care. This paper reviews existing guideline recommendations and recently published research related to two parameters of care: 1) first-line treatment of multiepisode psychosis and 2) the care of treatment-resistant patients. Its purpose is to help clinicians understand the implications of the latest research for the content of schizophrenia guidelines and for the clinical practice they are supposed to inform.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880864     DOI: 10.1007/s11920-007-0039-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  32 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 2.  Strategies for maximizing clinical effectiveness in the treatment of schizophrenia.

Authors:  Rajiv Tandon; Steven D Targum; Henry A Nasrallah; Ruth Ross
Journal:  J Psychiatr Pract       Date:  2006-11       Impact factor: 1.325

3.  Schizophrenia practice guidelines: international survey and comparison.

Authors:  Wolfgang Gaebel; Stefan Weinmann; Norman Sartorius; Wolfgang Rutz; John S McIntyre
Journal:  Br J Psychiatry       Date:  2005-09       Impact factor: 9.319

4.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

5.  Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Authors:  S W Lewis; L Davies; P B Jones; T R E Barnes; R M Murray; R Kerwin; D Taylor; K P Hayhurst; A Markwick; H Lloyd; G Dunn
Journal:  Health Technol Assess       Date:  2006-05       Impact factor: 4.014

6.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Authors:  Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; T Scott Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

7.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

8.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Authors:  Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

9.  Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

Authors:  Martin Knapp; Derek King; Klaus Pugner; Pablo Lapuerta
Journal:  Br J Psychiatry       Date:  2004-06       Impact factor: 9.319

10.  Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.

Authors:  Craig W Colton; Ronald W Manderscheid
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.